Cell Therapy – Page 2

Takeda to Cut 137 Staffers After Exiting Cell Therapy Research

2 months ago talkbio0Tagged Cell Therapy, Exit, Industry, layoffs, Massachusetts (geographic location), pipeline shake-up, portfolio reprioritization, R&D, restructuring, strategic, Takeda

Takeda; layoffs; cell therapy exit; biotech industry; restructuring; Massachusetts R&D; strategic portfolio reprioritization; pipeline shake-up

Curtain Closes on Takeda’s Cell Therapy Efforts

2 months ago talkbio0Tagged Biological Factors, Cell Therapy, Gamma/Delta T-Lymphocyte, Impaired, research discontinuation, strategic shift, Takeda

Takeda; cell therapy; research discontinuation; impairment loss; gamma delta T-cell; strategic shift; biopharmaceuticals

Novo Nordisk Terminates $598M Heart Failure Cell Therapy Collaboration with Heartseed Amid Major Restructuring

2 months ago talkbio0Tagged Biotechnology, Cardiospermum grandiflorum, Cell Therapy, Collaboration termination, Diabetes, Heart failure, HS-001, Maziar Mike Doustdar, Nordisk, Obesity, strategic restructuring

Novo Nordisk; Heartseed; heart failure; cell therapy; HS-001; collaboration termination; strategic restructuring; Maziar Mike Doustdar; diabetes; obesity; biotechnology

ArsenalBio Lays Off 50% of Staff in Major Strategic Pivot

3 months ago talkbio0Tagged AB-2100, ArsenalBio, Cell Therapy, Clinical Trials, layoffs, Myers, restructuring, Squibb partnership, Staff

ArsenalBio; layoffs; biotech; staff reduction; restructuring; cell therapy; AB-2100; clinical trials; Bristol Myers Squibb partnership

Capricor Claims FDA Misinterpreted Efficacy Data Leading to Rejection of DMD Therapy

3 months ago talkbio0Tagged Capricor Therapeutics, Cell Therapy, Clinical Trials, data misinterpretation, deramiocel, Effectiveness, Endpoints, HOPE-2 trial, Muscular Dystrophy, Duchenne, Non-Parametric Test, Rejection, Statistical Significance, United States Food and Drug Administration

Capricor Therapeutics; FDA rejection; deramiocel; Duchenne muscular dystrophy (DMD); efficacy data misinterpretation; clinical trial endpoints; HOPE-2 trial; non-parametric test; statistical significance; cell therapy

Appia Bio Shuts Down Before Reaching Clinical Trials Amid Biotech Funding Crunch

4 months ago talkbio0Tagged Appia Bio, biotech closures, Cell Therapy, Clinical Trials, Indonesian language, Kite Pharma partnership, Neoplasms

Appia Bio; cell therapy; biotech shutdown; funding challenges; clinical trials; Kite Pharma partnership; oncology; biotech closures; IND application

Funding Drought Puts Pressure on Cell Therapy Startups Like Appia Bio

4 months ago talkbio0Tagged ACUA, Appia Bio, CAR-iNKT cells, Cell Therapy, Droughts, financing characteristics, venture

Appia Bio; cell therapy; funding drought; biotech; venture capital; Series A financing; ACUA platform; CAR-iNKT cells

Recent Advances for Confident Cell Line Transfer

4 months ago talkbio0Tagged Biomechanical compliance, cell line development, Cell Therapy, cell transfer, clone stability, Electroporation, Guanosine Monophosphate, quality assurance, Transfection

cell line development; cell transfer; clone stability; electroporation; transfection; quality assurance; GMP compliance; cell therapy

Gilead’s Kite to Acquire Interius for $350M, Advancing In Vivo CAR-T Therapy

4 months ago talkbio0Tagged Acquisition, CAR-T, CAR-T therapy, Cell Therapy, Gilead, in vivo, Interius BioTherapeutics, Kite, device (physical object), Tecartus, Yescarta

Gilead; Kite; Interius BioTherapeutics; CAR-T therapy; in vivo CAR-T; acquisition; off-the-shelf cell therapy; $350 million; biotech; Yescarta; Tecartus; cell therapy platform

Genentech to End $2B Cell Therapy Collaboration with Adaptive Biotechnologies

4 months ago talkbio0Tagged Adaptive Biotechnologies, Cell Therapy, Collaboration termination, genentech, personalized cancer, T-Cell Receptor, TruTCR

Genentech; Adaptive Biotechnologies; cell therapy; collaboration termination; T-cell receptor; TruTCR platform; personalized cancer therapy; $2 billion deal